Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls-Reference-Cited by-同舟云学术

Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls

Published:2022-04 Issue:4 Volume:32 Page:271-283
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Muntoni Francesco,Signorovitch James,Sajeev Gautam,Goemans Nathalie^ORCID,Wong Brenda^ORCID,Tian Cuixia,Mercuri Eugenio,Done Nicolae^ORCID,Wong Hallee,Moss Jackson,Yao Zhiwen,Ward Susan J.,Manzur Adnan,Servais Laurent,Niks Erik H.^ORCID,Straub Volker,de Groot Imelda JM,McDonald Craig

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference51 articles.

1. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions;Wu;Pharmacoepidemiol Drug Saf,2020

2. FDA approves first treatment for a form of Batten disease,2017

3. Drug approval package: Myozyme (Alglucosidase Alfa),2006

4. The use of external controls in FDA regulatory decision making;Jahanshahi;Ther Innov Regul Sci,2021

5. Viewpoint: randomised controlled trials using invasive ‘placebo’ controls are unethical and should be excluded from Cochrane Reviews;Cyna;Cochrane Database Syst Rev,2011

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Dutch Dystrophinopathy Database: A National Registry with Standardized Patient and Clinician Reported Real-World Data;Journal of Neuromuscular Diseases;2024-09-03

2. Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021;Orphanet Journal of Rare Diseases;2024-08-24

3. “If you cannot measure it, you cannot improve it”. Outcome measures in Duchenne Muscular Dystrophy: current and future perspectives;Acta Neurologica Belgica;2024-07-31

4. Current Challenges of Using Patient-Level Claims and Electronic Health Record Data for the Longitudinal Evaluation of Duchenne Muscular Dystrophy Outcomes;Advances in Therapy;2024-07-30

5. Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study;PLOS ONE;2024-07-10